References

Christen, Deborah, Johannes Lübke, Anne Kaiser, et al. 2023. “Allogeneic Hematopoietic Stem Cell Transplantation in Advanced Systemic Mastocytosis.” Blood 142 (Supplement 1): 3605–5. https://doi.org/10.1182/blood-2023-178304.

DeAngelo, Daniel J., Jason Gotlib, Vinod Pullarkat, et al. 2024. “Apex Part 1: Updated Assessment of Bezuclastinib (CGT9486), a Selective KIT D816V Tyrosine Kinase Inhibitor, in Patients with Advanced Systemic Mastocytosis (AdvSM).” Blood 144 (Supplement 1): 659–59. https://doi.org/10.1182/blood-2024-193678.

DeAngelo, Daniel J., Deepti H. Radia, Tracy I. George, et al. 2021. “Safety and Efficacy of Avapritinib in Advanced Systemic Mastocytosis: The Phase 1 EXPLORER Trial.” Nature Medicine 27 (12): 2183–91. https://doi.org/10.1038/s41591-021-01538-9.

DeAngelo, Daniel J., Andreas Reiter, Tracy I. George, et al. 2022. “AZURE: A Phase 1/2 Study of Blu-263 as Monotherapy and in Combination with Azacitidine in Patients with Advanced Systemic Mastocytosis.” Blood 140 (Supplement 1): 6877–78. https://doi.org/10.1182/blood-2022-167410.

González-de-Olano, David, Paula Navarro-Navarro, Javier I. Muñoz-González, et al. 2023. “Clinical Impact of the TPSAB1 Genotype in Mast Cell Diseases: A REMA Study in a Cohort of 959 Individuals.” Allergy 79 (3): 711–23. https://doi.org/10.1111/all.15911.

Gotlib, Jason, Mariana Castells, Hanneke Oude Elberink, et al. 2023. “Avapritinib Versus Placebo in Indolent Systemic Mastocytosis.” NEJM Evidence 2 (6). https://doi.org/10.1056/evidoa2200339.

Gotlib, Jason, Andreas Reiter, Deepti H. Radia, et al. 2021. “Efficacy and Safety of Avapritinib in Advanced Systemic Mastocytosis: Interim Analysis of the Phase 2 PATHFINDER Trial.” Nature Medicine 27 (12): 2192–99. https://doi.org/10.1038/s41591-021-01539-8.

Knuth, Donald E. 1984. “Literate Programming.” Comput. J. (USA) 27 (2): 97–111. https://doi.org/10.1093/comjnl/27.2.97.

Lübke, J, T I George, D J DeAngelo, et al. 2025. “Disease-Modifying Effects of Avapritinib in Patients with Advanced Systemic Mastocytosis: Improvements in Bone Density.” Osteologie, ahead of print, March 21. https://doi.org/10.1055/s-0045-1804962.

Luebke, Johannes, Tracy I. George, Daniel J. DeAngelo, et al. 2024. “Disease-Modifying Effects of Avapritinib in Patients with Advanced Systemic Mastocytosis: Improvements in Bone Density.” Blood 144 (Supplement 1): 4544–44. https://doi.org/10.1182/blood-2024-193774.

Ustun, Celalettin, Andreas Reiter, Bart L. Scott, et al. 2014. “Hematopoietic Stem-Cell Transplantation for Advanced Systemic Mastocytosis.” Journal of Clinical Oncology 32 (29): 3264–74. https://doi.org/10.1200/jco.2014.55.2018.